

GENENTECH, INC
GENENTECH, INC.
GENENTECH, INC.
GENENTECH, INC.

RECEIVED
CENTRAL FAX CENTER

FEB 26 2004

OFFICIAL

1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-4462
TWX 9103717168

LEGAL DEPARTMENT

FAX NUMBERS (650) - 952-9881 OR (650) - 952-9882

DATE: February 26, 2004

Please deliver the following page(s) to:

NAME: Examiner Misook Yu, Group Art Unit 1642

FIRM: U.S. Patent and Trademark Office

NUMBER TRANSMITTING TO: (703) 872-9306

FROM: Lee K. Tan, Ph.D.; Reg. No. 39,447

NUMBER OF PAGES INCLUDING THIS COVER SHEET: 8

CONFIDENTIALITY NOTE


The documents accompanying this facsimile transmission contain information from GENENTECH, INC. which is confidential or privileged. This information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this faxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the documents to us and the retransmission of them to the intended recipient.

COMMENTS:

Re: Genentech Docket No.: P1777R1
Devaux et al.
Serial No. 09/698,705
Filed: October 27, 2000
Title: ANTI-TUMOR ANTIBODY COMPOSITIONS AND METHODS OF USE
Confirmation No.: 6130
Genentech Customer No.: 09157

If you did not receive all of the pages, please call Janet Tse as soon as possible at (650) 225-2906, Legal Department.

Patent Docket P1777R1
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Devaux et al. Serial No.: 09/698,705 Filed: October 27, 2000 For: ANTI-TUMOR ANTIBODY COMPOSITIONS AND METHODS OF USE	Group Art Unit: 1642 Examiner: M. Yu Confirmation No: 6130 Customer No: 09157 CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office Fax No. (703)872-9306 on February 26, 2004  Janet Tse
--	---

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

On Friday, February 20, 2004 Janet Tse (assistant to Lee Tan) spoke with Examiner Yu on the phone. It was confirmed that our Reply to Office Action dated September 30, 2003; and our Supplemental Response dated October 24, 2003 have not been paired with the file at the USPTO. As requested by Examiner Yu, we submit herewith copies of each of the above mentioned documents along with their respective postcard receipts bearing the USPTO stamp verifying that these documents were received at the USPTO. We respectfully request that these responses be entered into the file.

In view of the delay due to these papers being lost at the USPTO, the undersigned would appreciate expedited consideration of Applicants' responses of September 30 and October 24, 2003.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: February 26, 2004

By: 

Lee K. Tan, Ph.D.


Reg. No. 39,447

Telephone No. (650) 225-4462

OFFICIAL

Patent Docket No. PP1777R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of Devaux et al. Serial No.: 09/968,705 ⁶⁹⁸⁷⁰⁵ Filed: October 27, 2000 For: ANTI-TUMOR ANTIBODY COMPOSITIONS AND METHODS OF USE</p>	<p>Group Art Unit: 1642 Examiner: M. Yu Customer No. 09157 Confirmation No. 6130</p>	<p>RECEIVED CENTRAL FAX CENTER FEB 26 2004</p>
<p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box *, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 30, 2003  Janet Tse</p>		

REPLY TO OFFICE ACTION UNDER 37 CFR §1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is responsive to the Office Action dated July 29, 2003, in connection with the above-identified application. A response to this Action is due October 29, 2003.

Reconsideration of the application is respectfully requested in view of the remarks submitted herein.

REMARKSStatus of the claims

Claims 15, 18-21, and 30-32 are pending and have been rejected solely under 35 U.S.C. §112, first paragraph. Specifically, the rejection relates to the deposit of cell lines recited in the claims. The Examiner states that the specific cell lines must be readily available to the public but